ONCAlert | 2018 ASCO Annual Meeting
Conference  >  2016 SITC Meeting  >  

Impact of the KEYNOTE-045 Study Comparing Pembrolizumab and Chemotherapy in Bladder Cancer

Joaquim Bellmunt, MD, PhD
Published Online: 7:45 PM, Wed November 16, 2016

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses the impact of the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma. All patients in the study had recurred or progressed following platinum-based chemotherapy.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.